维奈托克治疗复发急性未分化白血病的疗效。
Activity of venetoclax against relapsed acute undifferentiated leukemia.
机构信息
Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
出版信息
Cancer. 2021 Aug 1;127(15):2608-2611. doi: 10.1002/cncr.33531. Epub 2021 Apr 6.
Abstract
Acute undifferentiated leukemia is a rare hematologic malignancy with a poor prognosis. Venetoclax was highly active in two patients with relapsed acute undifferentiated leukemia and should be studied further.
摘要
急性未分化白血病是一种罕见的血液系统恶性肿瘤，预后较差。维奈托克在两名复发的急性未分化白血病患者中具有高度活性，应进一步研究。
相似文献
1
Activity of venetoclax against relapsed acute undifferentiated leukemia.维奈托克治疗复发急性未分化白血病的疗效。
Cancer. 2021 Aug 1;127(15):2608-2611. doi: 10.1002/cncr.33531. Epub 2021 Apr 6.
2
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.维奈克拉与阿扎胞苷联合用药是复发/难治性急性髓系白血病患者移植策略的有效过渡方案。
Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.
3
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
4
Is venetoclax the new backbone of acute myeloid leukaemia therapy?维奈克拉会成为急性髓系白血病治疗的新支柱吗？
Lancet Haematol. 2021 Aug;8(8):e536-e537. doi: 10.1016/S2352-3026(21)00205-2.
5
Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.维奈克拉治疗急性髓系白血病：超越 VIALE-A。
Am J Hematol. 2024 Apr;99(4):515-518. doi: 10.1002/ajh.27256. Epub 2024 Feb 20.
6
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].维奈克拉与阿扎胞苷治疗难治性和复发性急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.
7
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.维奈托克单药治疗以及联合去甲基化药物或低剂量阿糖胞苷用于复发和难治性急性髓系白血病的系统评价和荟萃分析
Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.
8
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.使用地西他滨/维奈克拉和达雷妥尤单抗治疗与治疗相关的急性髓系白血病及潜在的多发性骨髓瘤。
Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13.
9
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.复发或难治性急性髓系白血病成人患者中，去甲基化药物/维奈克拉与强化化疗的比较
Br J Haematol. 2022 Aug;198(3):e35-e37. doi: 10.1111/bjh.18229. Epub 2022 May 4.
10
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.接受阿扎胞苷和维奈克拉治疗的复发/难治性白血病儿科患者的临床反应
Haematologica. 2023 Nov 1;108(11):3142-3147. doi: 10.3324/haematol.2022.282637.
引用本文的文献
1
Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.维奈托克用于难治性、耐药性儿童PICALM::MLLT10+ B细胞急性淋巴细胞白血病的缓解诱导
Leukemia. 2025 Jun;39(6):1520-1525. doi: 10.1038/s41375-025-02591-w. Epub 2025 Apr 15.
2
Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?维奈托克：高危髓系恶性肿瘤患儿治疗的新选择？
Blood Adv. 2024 Jul 9;8(13):3583-3595. doi: 10.1182/bloodadvances.2023012041.
本文引用的文献
1
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
2
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.维奈克拉联合阿糖胞苷和/或伊达比星治疗复发/难治性儿童急性髓系白血病的 1 期、剂量递增研究。
Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11.
3
Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database.急性未分化白血病：基于大型人群数据库的发病率和结局数据。
Leuk Res. 2020 Feb;89:106301. doi: 10.1016/j.leukres.2020.106301. Epub 2020 Jan 17.
4
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.基于表型的药物筛选揭示了维奈托克反应与急性髓系白血病分化阶段之间的关联。
Haematologica. 2020 Mar;105(3):708-720. doi: 10.3324/haematol.2018.214882. Epub 2019 Jul 11.
5
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.维奈克拉联合阿扎胞苷可破坏急性髓系白血病患者的能量代谢并靶向白血病干细胞。
Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12.
6
Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后急性未分化白血病患者的结局
Leuk Lymphoma. 2018 Dec;59(12):3006-3009. doi: 10.1080/10428194.2018.1441410. Epub 2018 Apr 4.
7
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.维奈托克单药治疗急性髓性白血病患者的II期研究中的疗效及反应的生物学关联
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.
8
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
9
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.ABT-199 选择性抑制 BCL-2 导致急性髓系白血病的靶细胞死亡。
Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.
10
BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.BH3 分析——测量线粒体凋亡途径的综合功能，以预测细胞命运决策。
Cancer Lett. 2013 May 28;332(2):202-5. doi: 10.1016/j.canlet.2011.12.021. Epub 2012 Jan 8.
Zotero 插件